A precision engineered interleukin-2 (IL-2) for bolstering CD8+ T- and NK-cell activity without eosinophilia and vascular leak syndrome in non-human primates.
Ma L, Acuff NV, Joseph IB, Ptacin JL, Caffaro CE, San Jose KM, Aerni HR, Carrio R, Byers AM, Herman RW, Pavlova Y, Pena MJ, Chen DB, Buetz C, Ismaili TK, Pham HV, Cucchetti M, Sassoon I, Koriazova LK, Leveque JA, Shawver LK, Mooney JM, Milla ME.
Ma L, et al. Among authors: chen db.
Cancer Res Commun. 2024 Sep 25. doi: 10.1158/2767-9764.CRC-24-0278. Online ahead of print.
Cancer Res Commun. 2024.
PMID: 39320047